Computational protein design of robust and scalable recombinant HRP and poly-HRP reagents

Active Grant Awarded

Award ID
R43GM163512
Recipient
Awarding agency
Obligated
$330,955

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date 33% complete
Place of performance
Seattle, WA 98109, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of General Medical Sciences awarded Monod Bio, Inc. $330,955 on July 23, 2026, under Assistance Listing 93.859, Biomedical Research and Research Training, for Grant R43GM163512, with an ultimate completion date of July 31, 2027. The award is a Small Business Innovation Research Phase I project to develop computational protein design of robust, scalable recombinant horseradish peroxidase (HRP) and poly-HRP reagents. The source positions these reagents as replacements for root-derived HRP, whose isoenzyme variability compromises reproducibility in diagnostic and research assays. Planned work includes designing a stable, de novo HRP enzyme that can be expressed efficiently in microbial systems and developing a self-assembling HRP nanoparticle that controls enzyme stoichiometry and performance consistency. The design also enables genetic fusions with other functional domains. Place of performance is Seattle, Washington 98109.

Description

Abstract
Horseradish peroxidase (HRP) is a critical reporter enzyme widely used in diagnostics, and research tools due to its ability to amplify signal in assays like elisas, western blots, and immunohistochemistry. However, current HRP reagents are largely derived from horseradish root, which results in heterogeneous mixtures of isoenzymes with varying glycosylation patterns, activity, and stability. This variability compromises reproducibility, complicates regulatory compliance, and presents significant manufacturing challenges. Moreover, recombinant HRP production has been historically hindered by its complex structural requirements, including the incorporation of a heme cofactor, multiple disulfide bonds, calcium ions, and glycosylation, which are difficult to replicate in microbial hosts. As a result, efforts to create a consistent, recombinant HRP alternative have proven unsuccessful, with current solutions like poly-HRP showing significant limitations in batch-to-batch consistency which is critical in high sensitivity assays. This sbir phase I project aims to overcome these challenges by using state-of-the-art computational protein design to develop a novel recombinant HRP mimetic that exhibits high stability, catalytically active properties, and scalability. Our approach involves two primary innovations: the design of a stable, DE novo HRP enzyme that can be expressed efficiently in microbial systems, and the development of a self-assembling HRP nanoparticle that enables precise control of enzyme stoichiometry and enhances performance consistency. The proposed HRP mimetic will not only ensure high-quality production of HRP reagents but also enable genetic fusions with other functional domains, opening the door to more consistent and reliable diagnostic development. Our team has developed promising preliminary data indicating a highly DE-risked application that will have a big impact. Our preliminary data demonstrate the feasibility of using computational protein design to create a DE novo HRP that is easy to manufacture, and with this grant, we intend to transform IT into a high-impact product with broad applications.

Quick answers

Who received award R43GM163512?

R43GM163512 was awarded to Monod Bio, Inc. by National Institute of General Medical Sciences (National Institutes of Health) on July 23, 2026.

How much is award R43GM163512 worth?

$330,955 has been obligated on R43GM163512.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award